Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 19 , ISSUE 10 ( 2015 ) > List of Articles

RESEARCH ARTICLE

Pharmacokinetic/pharmacodynamic profiling of imipenem in patients admitted to an intensive care unit in India: A nonrandomized, cross-sectional, analytical, open-labeled study

B. Abhilash, Chakra Tripathi, Anoop Gogia, Girish Meshram, Manu Kumar, B. Suraj

Keywords : Antibiotic-resistance, critically ill patients, imipenem, intensive care unit, pharmacokinetics/pharmacodynamics

Citation Information : Abhilash B, Tripathi C, Gogia A, Meshram G, Kumar M, Suraj B. Pharmacokinetic/pharmacodynamic profiling of imipenem in patients admitted to an intensive care unit in India: A nonrandomized, cross-sectional, analytical, open-labeled study. Indian J Crit Care Med 2015; 19 (10):587-592.

DOI: 10.4103/0972-5229.167036

License: CC BY-ND 3.0

Published Online: 01-10-2015

Copyright Statement:  Copyright © 2015; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Background and Aim: Widespread use of imipenem in intensive care units (ICUs) in India has led to the development of numerous carbapenemase-producing strains of pathogens. The altered pathophysiological state in critically ill patients could lead to subtherapeutic antibiotic levels. Hence, the aim of this study was to investigate the variability in the pharmacokinetic and pharmacodynamic profile of imipenem in critically ill patients admitted to an ICU in India. Materials and Methods: Plasma concentration of imipenem was determined in critically ill patients using high performance liquid chromatography, at different time points, by grouping them according to their locus of infection. The elimination half-life (t½) and volume of distribution (V d) values were also computed. The patients with imipenem trough concentration values below the minimum inhibitory concentration (MIC) and 5 times the MIC for the isolated pathogen were determined. Results: The difference in the plasma imipenem concentration between the gastrointestinal and the nongastrointestinal groups was significant at 2 h (P = 0.015) following drug dosing; while the difference was significant between the skin/cellulitis and nonskin/cellulitus groups at 2 h (P = 0.008), after drug dosing. The imipenem levels were above the MIC and 5 times the MIC for the isolated organism in 96.67% and 50% of the patients, respectively. Conclusions: The pharmacokinetic profile of imipenem does not vary according to the locus of an infection in critically ill patients. Imipenem, 3 g/day intermittent dosing, maintains a plasma concentration which is adequate to treat most infections encountered in patients admitted to an ICU. However, a change in the dosing regimen is suggested for patients infected with organisms having MIC values above 4 mg/L.


PDF Share
  1. Gupta E, Mohanty S, Sood S, Dhawan B, Das BK, Kapil A. Emerging resistance to carbapenems in a tertiary care hospital in North India. Indian J Med Res 2006;124:95-8.
  2. Joynt GM, Lipman J, Gomersall CD, Young RJ, Wong EL, Gin T. The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. J Antimicrob Chemother 2001;47:421-9.
  3. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: An environmental point prevalence study. Lancet Infect Dis 2011;11:355-62.
  4. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: Epidemiology and prevention. Clin Infect Dis 2011;53:60-7.
  5. Belzberg H, Zhu J, Cornwell EE 3 rd, Murray JA, Sava J, Salim A, et al. Imipenem levels are not predictable in the critically ill patient. J Trauma 2004;56:111-7.
  6. Giannoni E, Moreillon P, Cotting J, Moessinger A, Bille J, Décosterd L, et al. Prospective determination of plasma imipenem concentrations in critically ill children. Antimicrob Agents Chemother 2006;50:2563-8.
  7. Lee LS, Kinzig-Schippers M, Nafziger AN, Ma L, Sörgel F, Jones RN, et al. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis 2010;68:251-8.
  8. Carlucci G, Biordi L, Bologna M. Human plasma and aqueous humor determination of imipenem by liquid chromatography with ultraviolet detection. J Liq Chromatogr 1993;16:2347-58.
  9. Biswal S, Mishra P, Malhotra S, Puri GD, Pandhi P. Drug utilization pattern in the intensive care unit of a tertiary care hospital. J Clin Pharmacol 2006;46:945-51.
  10. Garot D, Respaud R, Lanotte P, Simon N, Mercier E, Ehrmann S, et al. Population pharmacokinetics of ceftriaxone in critically ill septic patients: A reappraisal. Br J Clin Pharmacol 2011;72:758-67.
  11. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986;108 (5 Pt 2):835-40.
  12. Norrby SR, Björnegård B, Ferber F, Jones KH. Pharmacokinetics of imipenem in healthy volunteers. J Antimicrob Chemother 1983;12 Suppl D: 109-24.
  13. Lefeuvre S, Marchand S, Lamarche I, Mimoz O, Couet W. Microdialysis study of imipenem distribution in the intraperitoneal fluid of rats with or without experimental peritonitis. Antimicrob Agents Chemother 2006;50:34-7.
  14. Wathen CG, Carbarns NJ, Jones PA, Millar A, Croughan MJ, Calder MA, et al. Imipenem-cilastatin in the treatment of respiratory infections in patients with chronic airways obstruction. J Antimicrob Chemother 1988;21:107-12.
  15. Sakka SG, Glauner AK, Bulitta JB, Kinzig-Schippers M, Pfister W, Drusano GL, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007;51:3304-10.
  16. Sexton DJ, Wlodaver CG, Tobey LE, Yangco BG, Graziani AL, MacGregor RR. Twice daily intramuscular imipenem/cilastatin in the treatment of skin and soft tissue infections. Chemotherapy 1991;37 Suppl 2:26-30.
  17. Craig WA. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.
  18. Jaruratanasirikul S, Raungsri N, Punyo J, Sriwiriyajan S. Pharmacokinetics of imipenem in healthy volunteers following administration by 2 h or 0.5 h infusion. J Antimicrob Chemother 2005;56:1163-5.
  19. van Zanten AR, Oudijk M, Nohlmans-Paulssen MK, van der Meer YG, Girbes AR, Polderman KH. Continuous vs. intermittent cefotaxime administration in patients with chronic obstructive pulmonary disease and respiratory tract infections: Pharmacokinetics/pharmacodynamics, bacterial susceptibility and clinical efficacy. Br J Clin Pharmacol 2007;63:100-9.
  20. Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. Trends Microbiol 2011;19:588-95.
  21. Mouton JW, den Hollander JG. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1994;38:931-6.
  22. Rodloff AC, Goldstein EJ, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother 2006;58:916-29.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.